Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

Author： Bose Prithviraj   Simmons Gary L   Grant Steven  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.22, Iss.6, 2013-09, pp. : 723-738

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status

By Kelland L.R.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 12, 2000-12 ,pp. : 2903-2911

Informa Healthcare

Access to resources Recommend Favorite

Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy

By  

Mini Reviews in Medicinal Chemistry, Vol. 10, Iss. 11, 2010-10 ,pp. : 1058-1070

Bentham Science Publishers

Access to resources Recommend Favorite

Cyclin-Dependent Kinase Inhibition by Flavoalkaloids

By  

Mini Reviews in Medicinal Chemistry, Vol. 12, Iss. 7, 2012-06 ,pp. : 632-649

Bentham Science Publishers

Access to resources Recommend Favorite

The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs

By  

Current Cancer Drug Targets, Vol. 12, Iss. 2, 2012-02 ,pp. : 85-96

Bentham Science Publishers

Access to resources Recommend Favorite

Antiangiogenic Therapy in Hematologic Malignancies

By  

Current Pharmaceutical Design, Vol. 10, Iss. 11, 2004-04 ,pp. : 1221-1234

Bentham Science Publishers

Access to resources Recommend Favorite